What is the appropriate medication regimen and dosing for a patient with decompensated heart failure?

Prescription for Decompensated Heart Failure

For acute decompensated heart failure, immediately initiate intravenous loop diuretics (furosemide 20-40 mg IV for diuretic-naive patients, or at least equivalent to the home oral dose for those already on diuretics), continue existing ACE inhibitors/beta-blockers unless hemodynamically unstable, and aggressively pursue complete decongestion as the primary therapeutic goal. 1

Immediate Diuretic Management

Start with IV loop diuretics as the cornerstone of therapy:

• For patients NOT on chronic diuretics: Begin with furosemide 20-40 mg IV 1
• For patients already on oral diuretics: Use at least the equivalent of their home oral dose IV 1
• Administer either as intermittent boluses or continuous infusion, adjusting based on clinical response 1
• Monitor urine output, symptoms, renal function, and electrolytes regularly 1

If inadequate response to >240 mg IV furosemide daily:

• Increase frequency or dose of IV boluses 2
• Add thiazide diuretic (hydrochlorothiazide or metolazone) 2
• Consider continuous IV furosemide infusion 2

The 2016 ESC guidelines 1 provide the most current evidence-based approach, superseding older recommendations. Recent research shows wide variation in diuretic dosing practices 3, but the guideline-directed approach remains clear: aggressive diuresis with close monitoring.

Neurohormonal Blockade During Decompensation

Continue ACE inhibitors and beta-blockers unless contraindicated:

• In worsening chronic HFrEF, maintain evidence-based disease-modifying therapies unless hemodynamic instability or contraindications exist 1
• Beta-blockers may require dose reduction but should NOT be discontinued unless cardiogenic shock is present 4
• If hypotensive, reduce other medications first before decreasing beta-blocker dose 4

This represents a critical shift from older practices. The 2022 AHA/ACC guidelines 5 and 2016 ESC guidelines 1 emphasize continuation of these mortality-reducing medications during acute decompensation.

Vasodilator Therapy (If Blood Pressure Permits)

For patients WITHOUT systemic hypotension:

• Consider IV nitroglycerin or nitroprusside as adjuvant to diuretics for dyspnea relief 5
• Particularly useful in hypertensive heart failure, coronary ischemia, or significant mitral regurgitation 5
• Caution: Nitroprusside requires arterial line monitoring and ICU setting; tachyphylaxis develops with nitroglycerin within 24 hours 5

These agents relieve symptoms but have NOT shown mortality benefit or reduced rehospitalization 5. Use is limited to symptomatic relief in normotensive/hypertensive patients.

Inotropic Support (Restricted Use)

Inotropes are NOT recommended unless:

• Symptomatic hypotension present 1
• Evidence of hypoperfusion/end-organ dysfunction 1

If required:

• Dobutamine for hypotension with poor tissue perfusion 6
• Milrinone preferred if significant pulmonary venous hypertension or patient on beta-blockers (phosphodiesterase inhibitors not antagonized by beta-blockade) 7

The evidence strongly discourages routine inotrope use due to safety concerns including arrhythmias and increased mortality 1.

Monitoring and Decongestion Targets

Assess daily:

• Body weight (target 1-2 kg loss daily until euvolemic)
• Urine output
• Jugular venous pressure
• Peripheral edema
• Lung examination for rales
• Renal function and electrolytes 1

Complete decongestion is the goal - do not consider patients "stabilized" if ongoing edema or congestion persists 3. This is a common pitfall where physicians prematurely accept partial decongestion.

Renal Function Management

If creatinine increases >30% from baseline:

• Review and potentially reduce doses of diuretics, ACE inhibitors, ARBs, and spironolactone 2
• Assess for reversible causes: NSAIDs, hypovolemia, hypotension, urinary obstruction 2
• In oliguric patients who are hemodynamically stable, review all nephrotoxic medications daily 2

If severe renal dysfunction (creatinine >250 μmol/L or >50% increase):

• Routine use of ACE inhibitors, ARBs, or spironolactone NOT recommended due to lack of efficacy evidence 2

Critical Pitfalls to Avoid

• Insufficient diuretic dosing: Only 7% of physicians use guideline-recommended doses (≥2× home dose) 3
• Premature discontinuation of beta-blockers: Continue unless cardiogenic shock
• Accepting partial decongestion: One-third of physicians consider patients with ongoing edema as "stabilized" 3
• Avoiding NSAIDs: These worsen heart failure and increase hospitalization risk 1
• Routine inotrope use: Reserve only for hypotension/hypoperfusion

Additional Supportive Measures

• VTE prophylaxis: Mandatory for all hospitalized heart failure patients 5
• Sodium restriction: Control intake in severe heart failure 8
• Avoid excessive fluids in severe HF 8